These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 3410355)

  • 21. A phase II trial of intraperitoneal cisplatin and etoposide for primary treatment of ovarian epithelial cancer.
    Howell SB; Kirmani S; Lucas WE; Zimm S; Goel R; Kim S; Horton MC; McVey L; Morris J; Weiss RJ
    J Clin Oncol; 1990 Jan; 8(1):137-45. PubMed ID: 2295904
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase II trial of intraperitoneal cisplatin with intravenous doxorubicin and cyclophosphamide in previously untreated patients with advanced ovarian cancer-long-term follow-up.
    Morgan RJ; Braly P; Cecchi G; Leong L; Shibata S; Margolin K; Somlo G; McNamara M; Longmate J; Schinke S; Raschko J; Nagasawa S; Kogut N; Parker P; Stein A; Cho J; Smith E; Coluzzi P; Najera L; Johnson D; Womack E; Doroshow JH
    Gynecol Oncol; 1999 Dec; 75(3):419-26. PubMed ID: 10600300
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intra-peritoneal cisplatin combined with intravenous paclitaxel in optimally debulked stage 3 ovarian cancer patients: an Izmir Oncology Group study.
    Unal OU; Yilmaz AU; Yavuzsen T; Akman T; Ellidokuz H
    Asian Pac J Cancer Prev; 2014; 15(15):6165-9. PubMed ID: 25124592
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of survival after second-line intraperitoneal cisplatin-based chemotherapy for advanced ovarian cancer.
    Piver MS; Recio FO; Baker TR; Driscoll D
    Cancer; 1994 Mar; 73(6):1693-8. PubMed ID: 7512437
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Second-line Intraperitoneal Platinum-based Therapy Leads to an Increase in Second-line Progression-free Survival for Epithelial Ovarian Cancer.
    Boisen MM; Lesnock JL; Richard SD; Beriwal S; Kelley JL; Zorn KK; Edwards RP
    Int J Gynecol Cancer; 2016 May; 26(4):626-31. PubMed ID: 27051048
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chemotherapy for murine ovarian cancer: a rationale for ip therapy with adriamycin.
    Ozols RF; Locker GY; Doroshow JH; Grotzinger KR; Myers CE; Fisher RI; Young RC
    Cancer Treat Rep; 1979 Feb; 63(2):269-73. PubMed ID: 445504
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer: a randomized trial of the Gruppo Oncologico Nord-Ovest.
    Gadducci A; Carnino F; Chiara S; Brunetti I; Tanganelli L; Romanini A; Bruzzone M; Conte PF
    Gynecol Oncol; 2000 Feb; 76(2):157-62. PubMed ID: 10637064
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Does intraperitoneal chemotherapy benefit optimally debulked epithelial ovarian cancer patients after neoadjuvant chemotherapy?
    Le T; Latifah H; Jolicoeur L; Weberpals J; Faught W; Hopkins L; Fung MF
    Gynecol Oncol; 2011 Jun; 121(3):451-4. PubMed ID: 21402403
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of hyperbaric oxygen as a chemosensitizer in the treatment of epithelial ovarian cancer in xenografts in mice.
    Alagoz T; Buller RE; Anderson B; Terrell KL; Squatrito RC; Niemann TH; Tatman DJ; Jebson P
    Cancer; 1995 May; 75(9):2313-22. PubMed ID: 7536123
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ovarian cancer in BRCA mutation carriers: improved outcome after intraperitoneal (IP) cisplatin.
    Kwa M; Edwards S; Downey A; Reich E; Wallach R; Curtin J; Muggia F
    Ann Surg Oncol; 2014 May; 21(5):1468-73. PubMed ID: 24081797
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combined intraperitoneal and intravenous chemotherapy for women with optimally debulked ovarian cancer: results from an intergroup phase II trial.
    Rothenberg ML; Liu PY; Braly PS; Wilczynski SP; Hannigan EV; Wadler S; Stuart G; Jiang C; Markman M; Alberts DS
    J Clin Oncol; 2003 Apr; 21(7):1313-9. PubMed ID: 12663720
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study.
    Walker JL; Armstrong DK; Huang HQ; Fowler J; Webster K; Burger RA; Clarke-Pearson D
    Gynecol Oncol; 2006 Jan; 100(1):27-32. PubMed ID: 16368440
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer.
    Alberts DS; Liu PY; Hannigan EV; O'Toole R; Williams SD; Young JA; Franklin EW; Clarke-Pearson DL; Malviya VK; DuBeshter B
    N Engl J Med; 1996 Dec; 335(26):1950-5. PubMed ID: 8960474
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Utilization of intraperitoneal chemotherapy for optimally cytoreduced advanced stage epithelial ovarian cancer: A 10-year single institution experience with a racially diverse urban population.
    Miller EM; Tymon-Rosario J; Xie X; Xue X; Gressel GM; Miller DT; Kuo DY; Nevadunsky NS
    Gynecol Oncol; 2017 Oct; 147(1):36-40. PubMed ID: 28751119
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cited rationale for variance in the use of primary intraperitoneal chemotherapy following optimal cytoreduction for stage III ovarian carcinoma at a high intraperitoneal chemotherapy utilization center.
    Schlappe BA; Mueller JJ; Zivanovic O; Gardner GJ; Long Roche K; Sonoda Y; Chi DS; O'Cearbhaill RE
    Gynecol Oncol; 2016 Jul; 142(1):13-18. PubMed ID: 27189456
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intraperitoneal cisplatin-based chemotherapy for ovarian carcinoma.
    Howell SB; Kirmani S; McClay EF; Kim S; Braly P; Plaxe S
    Semin Oncol; 1991 Feb; 18(1 Suppl 3):5-10. PubMed ID: 2003227
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic results of cisplatin IP and carboplatin IV with G-CSF in patients with ovarian cancer.
    Adachi S; Itani Y; Ito K; Noda T; Shintani M; Saito K; Furukawa N; Tomii Y
    Oncol Rep; 2001; 8(1):27-31. PubMed ID: 11115564
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ovarian cancer spheroid shrinkage following continuous exposure to cisplatin is a function of spheroid diameter.
    Tanenbaum LM; Mantzavinou A; Subramanyam KS; Del Carmen MG; Cima MJ
    Gynecol Oncol; 2017 Jul; 146(1):161-169. PubMed ID: 28499648
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of prognostic factors after positive second-look surgery in epithelial ovarian carcinoma.
    McCreath WA; Eisenhauer EL; Abu-Rustum NR; Venkatraman ES; Caceres A; Bier R; Huh J; Cho J; Barakat RR; Chi DS
    Gynecol Oncol; 2006 Jul; 102(1):8-14. PubMed ID: 16427689
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intraperitoneal cisplatin chemotherapy in the management of ovarian carcinoma.
    Markman M
    Semin Oncol; 1989 Aug; 16(4 Suppl 6):79-82. PubMed ID: 2669140
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.